Keyphrases
Placebo-controlled Randomized Trial
100%
Irbesartan
100%
AIMS™
100%
Marfan Syndrome
100%
Intravenous Lipid Emulsion
100%
Lipid Emulsion
100%
Drug Dependence
100%
In Vitro Study
100%
Bound Drug
40%
Protein Binding
40%
Free Drug
40%
Non-protein
40%
Plasma Samples
40%
Phosphate-buffered Saline
40%
Aortic Dilatation
27%
Partition Coefficient
20%
Clinical Exploration
20%
Free Drug Concentration
20%
Lipid Emulsion Therapy
20%
Number of Drugs
20%
Aqueous Phase
20%
Anesthetic Neurotoxicity
20%
Relative Amount
20%
Ramipril
20%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
20%
Inverse Correlation
20%
Cassette
20%
Marfan
18%
Difference in Mean
18%
Placebo Groups
18%
Placebo
18%
Aortic Root Dilatation
18%
Aortic Root Diameter
9%
Aortic Complication
9%
Aortic Diameter
9%
Serious Adverse Events
9%
Angiotensin II Type 1 Receptor (AT1R)
9%
Placebo-controlled
9%
Once-daily
9%
Rate of Change
9%
Double-blind Randomized Trial
9%
Echocardiography
9%
Beta-blockers
9%
British Heart Foundation
9%
Mean Blood Pressure
9%
Treatment Allocation
9%
Receptor Antagonist
9%
Older Adults
9%
Core Laboratory
9%
Pharmacology, Toxicology and Pharmaceutical Science
Marfan Syndrome
100%
Irbesartan
100%
Randomized Controlled Trial
100%
Placebo
100%
Lipid Emulsion
100%
Toxic Injury
100%
Phosphate Buffered Saline
28%
Ramipril
14%
Anesthetic Toxicity
14%
Drug Concentration
14%
Angiotensin 1 Receptor
9%
Adverse Event
9%